As the population ages and Alzheimer's disease (AD) becomes more prevalent, nursing facilities will be faced with managing more AD patients than in previous decades. Managing this population will pose a significant challenge for the resources of long-term care facilities. In short-and long-term studies, cholinesterase (ChE) inhibitor treatment has been shown to benefit the symptoms of mild to moderate AD. Donepezil trials have extended this finding to patients with moderate to severe AD as well as the more severe symptoms of AD patients residing in nursing home settings. Results from long-term ChE inhibitor trials and the benefits that may be gained by treating AD patients residing in nursing facilities are presented.
Galasko D: An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour. Eur J Neurol. 1998; 5 (suppl 4): S9-S17.
2.
Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999; 66: 137-147.
3.
Katzman R, Fox PJ: The world-wide impact of dementia: projections of prevalence and costs. In: Mayeux R, Christen Y, eds. Epidemiology of Alzheimer's disease: from gene to prevention. Heidelberg: Springer-Verlag; 1999: 1-17.
4.
Evans DA, Funkenstein HH, Albert MS, et al: Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989; 262: 2551-2556.
5.
Krauss N, Altman B: Research findings no. 5: Characteristics of nursing home residents—1996. Agency for Healthcare Research and Quality. Available at: http://www.meps.ahrq.gov/papers/rf5_99-0006/rf5.htm. Accessed May 29, 2001.
6.
Magaziner J, German P, Zimmerman SI, et al: The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in Nursing Homes Research Group. Gerontologist. 2000; 40(6): 663-672.
7.
Kleinman L, Schmier J, Rothman M, et al: Time and costs of managing specific disruptive behaviors in long-term care facilities: A descriptive study. Consult Pharm.2002; 17: 497-507.
8.
Rice DP, Fillit HM, Max W, et al: Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care. 2001; 7(8): 809-818.
9.
Hill J, Futterman R, Duttagupta S, et al: Alzheimer's disease and related dementias increase costs of comorbidities in managedmedicare. Neurology. 2002; 58: 62-70.
10.
Gutterman E, Markowitz J, Lewis B, Fillit H: Cost of Alzheimer's disease and related dementia in managed-medicare. J Am Geriatr Soc.1999; 47: 1065-1071.
11.
Doody RS, Stevens JC, Beck C, et al: Practice parameter: management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.2001; 56: 1154-1166.
12.
Rich JB, Rasmusson DX, Folstein MF, et al: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995; 45(1): 51-55.
13.
Sano M, Ernesto C, Thomas RG, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med.1997; 336: 1216-1222.
14.
Le Bars PL, Kieser M, Itil KZ: A 26-week analysis of a doubleblind, placebo-controlled trial of the ginkgo biloba extract EGb 761R in dementia. Dement Geriatr Cogn Disord.2000; 11: 230-237.
15.
Mulnard RA, Cotman CW, Kawas C, et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000; 283(8): 1007-1015.
16.
Farlow M, Gracon S, Hershey L, et al: A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992; 268(18): 2523-2529.
17.
Knapp M, Knopman D, Solomon P, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA.1994; 271(13): 985-991.
18.
Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998; 50(1): 136-145.
19.
Burns A, Rossor M, Hecker J, et al: The effects of donepezil in Alzheimer's disease—results from a multinational trial. Dement Geriatr Cogn Disord. 1999; 10(3): 237-244.
20.
Tariot P, Cummings J, Katz I, et al: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc.2001; 49: 1590-1599.
21.
Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57: 613-620.
22.
Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology.2000; 54(12): 2269-2276.
23.
Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ.2000; 321(7274): 1445-1449.
24.
Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Ger Psychopharmacol.1998; 1: 55-65.
25.
Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999; 318(7184): 633-638.
26.
Winblad B, Engedal K, Soininen H, et al: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001; 57: 489-495.
27.
Farlow M, Anand R, Messina JJ, et al: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol.2000; 44(4): 236-241.
28.
Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology.2000; 54(12): 2261-2268.
29.
Doody RS, Geldmacher DS, Gordon B, et al: Open-label, multicenter, Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol.2001; 58: 427-433.
30.
Rogers SL, Doody RS, Pratt RD, Ieni JR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol.2000; 10: 195-203.
31.
Mohs RC, Doody RS, Morris JC, et al: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology.2001; 57: 481-488.
32.
Rogers S, Friedhoff L: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996; 7(6): 293-303.
33.
Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med.1998; 158(9): 1021-1031.
34.
Farlow M, Hake A, Messina J, et al: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol.2001; 58(3): 417-422.
35.
Berg L, Miller J, Baty J, et al: Mild senile dementia of the Alzheimer type: 4. Evaluations of intervention. Ann Neurol. 1992; 31: 242-249.
36.
Feldman H, Gauthier S, Hecker J, et al.: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease, and the impact on caregiver burden. J Am Geriatr Soc. (In press).
37.
White H, Pieper C, Schmader K: The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc.1998; 46(10): 1223-1227.
